Khaja Mohiuddin, MD
Family Medicine · Savannah, GANPI 1669931598
Payments from drug & device makers
Across 320 payments — averaging $18.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$698
- Lilly USA, LLC$663
- AbbVie$652
- Pfizer$491
- Amgen$482
- Novartis$377
- plus $3K from 29 others
What the payments were for
- Food & beverage$5,887100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 54 | $698 |
| Lilly USA, LLC | 30 | $663 |
| AbbVie | 39 | $652 |
| Pfizer | 26 | $491 |
| Amgen | 34 | $482 |
| Novartis | 19 | $377 |
| AstraZeneca | 18 | $338 |
| Johnson & Johnson | 12 | $323 |
| Otsuka America Pharmaceutical, Inc. | 14 | $298 |
| Boehringer Ingelheim | 11 | $255 |
| Sumitomo Pharma America, Inc. | 6 | $168 |
| GSK | 8 | $140 |
| Exact Sciences | 7 | $129 |
| Astellas Pharma US Inc | 3 | $76 |
| Merck | 4 | $70 |
| Dexcom, Inc. | 4 | $69 |
| Idorsia Pharmaceuticals US Inc | 3 | $66 |
| Bayer | 3 | $56 |
| Mannkind Corporation | 1 | $54 |
| Eisai Inc. | 2 | $50 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $41 |
| Vanda Pharmaceuticals Inc. | 2 | $40 |
| Antares Pharma, Inc. | 2 | $39 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $38 |
| Phathom Pharmaceuticals, Inc. | 2 | $38 |
| Zealand Pharma US, Inc. | 2 | $37 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| Organon | 1 | $25 |
| Pacira Pharmaceuticals Incorporated | 1 | $24 |
| Abbott | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Radius Health, Inc. | 1 | $23 |
| Global Blood Therapeutics, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Corcept Therapeutics | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,887 in reported general payments places this provider in the 85th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 52 | $64,596 |
| MounjaroTirzepatide | 22 | $30,442 |
| EliquisApixaban | 15 | $24,542 |
| TrulicityDulaglutide | 17 | $20,977 |
| JardianceEmpagliflozin | 13 | $20,624 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $17,009 |
| EntrestoSacubitril/Valsartan | 15 | $8,836 |
| MyrbetriqMirabegron | 13 | $5,506 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 19 | $3,052 |
| SynthroidLevothyroxine Sodium | 26 | $2,734 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $2,664 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,651 |
| Atorvastatin Calcium | 179 | $1,976 |
| Gabapentin | 117 | $1,645 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 42 | $1,280 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $698 | $64,59652 claims |
| Lilly USA, LLCMounjaro, Trulicity | $663 | $51,41839 claims |
| PfizerEliquis | $491 | $24,54215 claims |
| Boehringer IngelheimJardiance | $255 | $20,62413 claims |
| GSKTrelegy Ellipta | $140 | $17,00927 claims |
| NovartisEntresto | $377 | $8,83615 claims |
| Astellas Pharma US IncMyrbetriq | $76 | $5,50613 claims |
| AbbVieSynthroid | $652 | $2,73426 claims |
| AstraZenecaSymbicort | $338 | $2,65111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Savannah
- Christopher OldfieldSavannah$6.4M
- Debbie HaginsSavannah$2.1M
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.